Long-term safety and seizure outcome in Japanese patients with Lennox–Gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial

Lennox-Gastaut syndrome (LGS) is an epileptic encephalopathy characterized by various types of epileptic seizures (mainly tonic seizures), diffuse slow spike-and-wave complex patterns on the electroencephalogram (EEG), and impairment of cognitive function. The long-term prognosis for mental function and seizures is generally devastating (Arzimanoglou et al., 2009; Beaumanoir, 1985; Blatter-Arifi, 1991; Oguni et al., 1996; Ohtsuka et al., 1990; Yagi, 1996). A high risk of sudden falls due to tonic and/or atonic seizures often affects the quality of life.

Source: Epilepsy Research - January 12, 2016 Category: Neurology Authors: Yoko Ohtsuka, Harumi Yoshinaga, Yukiyoshi Shirasaka, Rumiko Takayama, Hiroki Takano, Kuniaki Iyoda Source Type: research